Relenza — Competitive Intelligence Brief

Relenza (ZANAMIVIR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuraminidase Inhibitor [EPC]. Area: Infectious Disease.

marketed Neuraminidase Inhibitor [EPC] Sialidase 3 Infectious Disease Small molecule

Target snapshot

Relenza (ZANAMIVIR) — GSK. Relenza works by blocking the neuraminidase enzyme, preventing the influenza virus from spreading and infecting new cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Relenza TARGET	ZANAMIVIR	GSK	marketed	Neuraminidase Inhibitor [EPC]	Sialidase 3	1999-01-01
active oseltamivir	active oseltamivir	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
zanamivir for inhalation	zanamivir for inhalation	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Oseltamivir phosphate granules	Oseltamivir phosphate granules	China Academy of Chinese Medical Sciences	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Tamiflu®	Tamiflu®	Genuine Research Center, Egypt	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Oseltamivir(oral)	Oseltamivir(oral)	Guangdong Raynovent Biotech Co., Ltd	marketed	Neuraminidase inhibitor	Influenza neuraminidase
oseltamivir and chinese medicinal herbs	oseltamivir and chinese medicinal herbs	Capital Medical University	marketed	Neuraminidase inhibitor combined with herbal supplement	Influenza viral neuraminidase; herbal targets unknown

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuraminidase Inhibitor [EPC] class)

1. GSK · 1 drug in this class